Related Experiment Video
Updated: Sep 13, 2025
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Is ibuprofen associated with upper gastrointestinal bleeding? A systematic review and meta-analysis
Konstantinos Gkiouras1, Ioannis Myrogiannis2, Dimitrios Kouvelas2
1Laboratory of Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. kgkio@auth.gr.
Background:
Previous systematic reviews associated nonsteroidal anti-inflammatory drugs (NSAIDs) with upper gastrointestinal bleeding (UGIB) without comparing ibuprofen to paracetamol. We systematically reviewed and meta-analyzed studies comparing ibuprofen against paracetamol, placebo, non-users, or other NSAIDs on their association with UGIB.
Methods:
We searched PubMed, CENTRAL, Web of Science, Scopus, ClinicalTrials.gov, and WHO ICTRP for randomized clinical trials (RCTs) and observational studies and assessed their risk of bias. We utilized random-effects models, calculated odds ratios (OR) or risk ratios (RR) with their 95% confidence intervals (CI), and evaluated the certainty of the evidence.
Results:
We identified seven RCTs and 10 observational studies recruiting 89,522 participants. Ibuprofen intake ranged mostly from up to 1,200 mg to 1,800 mg daily, and its median exposure window was 1.5 weeks. After removing a potentially influential case, ibuprofen compared to paracetamol was not associated with UGIB (OR: 0.96, 95% CI: 0.36 to 2.59, p = 0.9341, I2: 0). However, ibuprofen was associated with UGIB compared to non-users (OR: 2.51, 95% CI: 1.33 to 4.74, p = 0.0047, I2: 89.11%) and selective NSAIDs (OR: 2.05, 95% CI: 1.18 to 3.55, p = 0.0191, I2: 11.50%). Additionally, ibuprofen compared to placebo (RR: 3.51, 95% CI: 0.56 to 22.23, p = 0.1820, I2: 0%) and non-selective NSAIDs (OR: 0.81, 95% CI: 0.62 to 1.07, p = 0.1254, I2: 15.37%) was not associated with UGIB. We found predominantly a high risk of bias and 'very low' certainty of evidence.
Conclusion:
Low-dose and short-term ibuprofen administration may not be associated with UGIB compared to paracetamol or other non-selective NSAIDs. Future research should investigate dose-response relationships.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...